U.S. Markets closed

The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018

NEW YORK, Sept. 18, 2019 /PRNewswire/ --

The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05815404/?utm_source=PRN

Factors such as, growing cancer prevalence across the globe, new product launches and benefits offered by generic drugs are boosting the market over the years. In addition, the growing pharmaceutical industry in developing countries are likely to have a positive impact on the growth of the market in the coming years.
Generic drugs are copies of branded drugs.Their pharmacological effects are similar to the branded counterparts.

Generic drugs are cost effective as the manufacturers have not invested in the development and marketing of the new drug.When a drug patent expires, other manufacturers apply for FDA approval in order to manufacture and sell the product.

Hence generic drugs are cheaper than branded drugs.The generic drug have exactly the same effects, dosage, side effects, route of administration, safety, risks, and strength as the original branded drug.

Generic drugs are important in oncology as some anticancer drugs are only offered as generics. In most of the cases like, children with acute lymphoblastic leukemia or women patients with early-stage breast cancer are treated with generics. Generic drugs are extensively used in supportive care. The most significant benefit of using generic drugs is the cost, which is up to 85% less than that of a branded drugs. Thus, these benefits offered by generic drugs is likely to enhance the market growth during the forecast period.
The global generic oncology drugs market, based on the indication was segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer, others.In 2018, the lung cancer segment held the largest share of the market, by indication.

The highest share of lung cancer segment attributes to the high prevalence of patients suffering with the lung cancer that can be treated with generic oncology drugs.
Some of the major primary and secondary sources included in the report for the Generic Oncology Drugs Market are the World Health Organization, British Generics Manufacturers Association, Centers for Disease Control and Prevention, Cancer Association of South Africa, Italian Association for Cancer Research, American Cancer Society, Indian Brand Equity Foundation, and others.

Read the full report: https://www.reportlinker.com/p05815404/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision

View original content:http://www.prnewswire.com/news-releases/the-global-generic-oncology-drugs-market-is-expected-to-reach-us-36-029-60-mn-in-2027-from-us-21-200-00-in-2018--300920962.html